Sensei Biotherapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sensei Biotherapeutics, Inc.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2015.
Fiscal 2013 was a difficult year for Asian drug producers. 2013 drug revenues were $128 billion, 5.1% down on 2012 levels ($136 billion) across the 85 publicly-traded pharmaceutical companies that constitute the Scrip Asia 100.
The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.
- Other Names / Subsidiaries
- Alvaxa Biosciences, Inc.
- Panacea Global, Inc.
- Panacea Pharmaceuticals, Inc.